Upload
others
View
17
Download
4
Embed Size (px)
Citation preview
Key Points in Blood and Blood Products Transfusion
Practice
Siti Rohayah SulaimanDepartment of Anaesthesia & Intensive Care,
HRPB, Ipoh
Overviewblood components
blood grouping
transfusion indication
administration of blood components
transfusion complication/reactions
summary
Blood Components
Packed red blood cells (PRBC)
Platelets
Fresh Frozen Plasma (FFP)
Cryoprecipitate (CP)
Cryo poor plasma (CPP)
1 unit of blood theoretically gives;
1 PRBC
1 FFP
1 random donor unit platelet
Storage Condition
PRBC : 4-6’C, shelf life 35 days
FFP/CPP : -40’C, shelf life 1 year
Cryoprecipitate : -40’C, shelf life 1 year
Platelet : 22-24’C on platelet agitator, shelf life 5 days
Blood Grouping:ABO & Rh Compatibility
4 types of blood group
O, A, B, AB
Group O - universal donor, but can only receive O
Group AB - universal recipient, but can only donate to AB
Rh -ve/Rh tve
Rh tve can receive Rh -ve blood, but Rh -ve can't receive Rh the blood
Blood & Blood Products Transfusion in Critically Ill
RBC transfusion>40% - receive RBC transfusion in ICU, 90% for stable anaemia
PRBC indications in ICU;
Acute haemorrhage with haemodynamic instability
Acute anaemia with evidence of inadequate O2 delivery - restless, obtundation, lactate acidosis, cool peripheries
Transfusion threshold Hb < 7-8 g/dL - depending on patient
based on Transfusion Requirement in Critical Care (TRICC) trial
833 critically ill patient, liberal (Hb<10 gm/dL) vs restrictive (Hb <7 gm/dL)
exceptional in acute myocardial ischaemia (Hb < 10 g/dL)
restrictive strategy reduce hospital mortality
2014 metanalysis - confirm TRICC trial finding
liberal transfusion Hb > 8 gm/dL, increase risk of nosocomial infection
co-morbic heart disease Hb <8.7 gm/dL, maintain Hb near 10 gm/dL in acute MI
NEJM, 2013 - Transfusion for acute UGIT bleeding
921 patients with UGIT bleed
randomly assigned RBC transfusion Hb<7 gm/dL vs Hb < 9 gm/dL
patients in lower trigger group, Hb<7 gm/dL had higher survival at 6 weeks, less ongoing bleeding & fewer complication
Potential efficacy of transfused RBC
circulatory (volume) effect
more immediate effect
not recommended as volume expander
rheological effect - blood flow/viscosity
important in maintaining microvascular circulation in severe haemodilution
improved oxygen transportation
improved Hb ~ 1 g/dL per unit RBC
not necessarily improved O2 delivery/consumption at tissue level
Platelet transfusionsProphylaxis
platelet <10x109/L without risk factors for bleeding
platelet <20x109/L with risk for bleeding
to maintain platelet > 50x109/L - for surgery/invansive procedure
Bleeding patient
any bleeding pt dt thrombocytopenia
platelet < 50x109/L in massive bleeding or transfusion
Plasma Transfusionportion of WB that remain after RBC & platelet removed
replacement of single factor deficiencies if specific factor not available
immediate reversal of warfarin induced anticoagulation - in active bleeding/urgent surgical procedure
indication in critically ill less established
active bleeding in setting of known or strongly suspected coagulation abnormalities
Massive transfusion of PRBC
prior to invasive surgical procedures with high risk of bleeding complications
invasive procedures with low risk of bleeding, INR > 2
Cryoprecipitate Transfusion
contain factor VIII, fibrinogen, von Willebrand, factor XIII & fibronectin
treatment of haemophilia, congenital/acquired hypofibrinogemia
liver disease, DIC, hyperfibrinolysis, massive transfusion
Safe & Effective Transfusiondefine indication & benefit
accurate pt identification for blood group and compatibility
identification & careful management of high risk pt
appropriate handling, administration & monitoring
infusion should not be associated with preventable ill effect
inform patient/relatives
aware of possible transfusion related complications
early diagnosis & intervention in adverse events of transfusion
documentation
Administration of blood component
must be checked against patient’s information detail
blood request form
case notes
wristband
Patient monitoring during transfusion
Vital signs - T, BP, PR - before, during and after transfusion
Closely observed during 1st 5-10 min of transfusion
RBC - 1st 50 mls - should transfused slowly
Unconscious patients - vital signs should be check at 15 min interval during transfusion
Periodically observed during transfusion for any acute transfusion reaction
Time limit for infusion of blood componentsRBC
risk of bacteria contamination at room T
start transfusion within 30 min after removing from blood refrigerator
should complete transfusion within 4 hrs
Platelet
keep at T 22-24, never keep in refrigerator
infusion should start as soon as received from blood bank and complete within 30 min
Plasma
start as soon as thawed
should complete as tolerated
Blood administration sets
all blood component - infused using administration set with integrated filter 170 micrometer, to trap any large aggregate
platelet - used new administration set
Blood warmers
reduce incidence of cardiac arrest/arrythmias dt massive transfusion of cold blood component
limited to multiple rapid transfusion >50 mls/kg/hr in adults, 15 mls/kg/hr in children, exchange transfusion
no evidence beneficial in slow infusion
should not be warm by placing in hot water, under running tap,
ComplicationsImmunologic reactions
Acute haemolytic reactions - 0.016%, ABO incompatibility, fatal.
pain at infusion site, fever, chills, back/substernal pain, dyspnea, changes in mental status, hypotension, cyanosis, bleeding
unconscious pt - unexplained hypotension, haematuria, bleeding
Delayed haemolytic reaction - more common (0.025%), mild, 35% undetected
Febrile nonhaemolytic reaction - 7% of RBC transfusion, dt anti leukocytes antibody, self limited
Allergic reaction - dt antigen to which patient has preexisting antibodies.
from mild urticaria to anaphylaxis
ComplicationsVolume overload
volume expansion, may lead to APO esp in cardiac and renal failure patient
Hypothermia
rapidly transfused cold blood product in acute bleeding, reduce core body T 32-35 C
cardiac arrest, arrythmias
Coagulopathy
in significant PRBC transfusion, early resuscitation with colloids/crystalloids
haemodilution, acidosis
replacement of blood product 1:1:1 ratio
ComplicationsCitrate toxicity
present in stored blood products
cause metabolic alkalosis and reduced plasma ionised calcium
Tranfusion related acute lung injury (TRALI)
alloreactive plasma antibodies/biologically active lipids, cause agglutination & activation of leukocytes —> ALI, APO
mild increase in O2 requirements to severe ARDS
Post transfusion purpura
rare disorder, thrombocytopenia develop after 7-10 days post transfusion
Transfusion Reaction
Transfusion Reaction
SummaryTransfusion of blood & blood products common in ICU
> 40% of patients receive one or more RBC transfusion while in ICU
Evidence indicates that a great numbers of patients being transfused RBC may not having benefit from transfusion - in improving clinical outcomes
Challenge lies in identifying patient at risk of complication from anaemia and transfusing them without exposing other patient to unwarranted risk of inappropriate transfusion
Indication for platelet and plasma transfusion not as clear as RBC transfusion
Better and safe transfusion practice should not be view as option, but necessity to ensure benefit than giving harm